Abstract:Qi Wang, 1– 3, &ast Jiaxin Dong, 4, &ast Mengxian Du, 1, 3, &ast Xinna Liu, 1– 3 Shiqi Zhang, 1 Di Zhang, 1, 3 Wanyun Qin, 1, 3 Xikun Xu, 1, 2 Xianghui Li, 1, 3 Ruidong Su, 1, 2 Leyi Qiu, 1, 2 Baoqiang Li, 4, 5 Huiping Yuan 1 1 Department of Ophthalmology, The Second Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China; 2 The Key Laboratory of Myocardial Ischemia, Harbin Medical University, Ministry Education, Harbin, People's Republic of China; 3 Future Medical Laboratory, the Second Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China; 4 Institute for Advanced Ceramics, State Key Laboratory of Urban Water Resource and Environment, Harbin Institute of Technology, Harbin, People's Republic of China; 5 Laboratory of Dynamics and Extreme Characteristics of Promising Nanostructured Materials, Saint Petersburg State University, St. Petersburg, Russia &astThese authors contributed equally to this work Correspondence: Huiping Yuan, Department of Ophthalmology, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150081, People's Republic of China, Email Baoqiang Li, Institute for Advanced Ceramics, State Key Laboratory of Urban Water Resource and Environment, Harbin Institute of Technology, Harbin, 150081, People's Republic of China, Email Introduction: Glaucoma is a prevalent cause of irreversible vision impairment, characterized by progressive retinal ganglion cells (RGCs) loss, with no currently available effective treatment. Rapamycin (RAPA), an autophagy inducer, has been reported to treat glaucoma in rodent models by promoting RGC survival, but its limited water solubility, systemic toxicity, and pre-treatment requirements hinder its potential clinical applications. Methods: Chitosan (CS)-RAPA carbon dot (CRCD) was synthesized via hydrothermal carbonization of CS and RAPA and characterized by transmission electron microscopy, Fourier transform infrared spectra, and proton nuclear magnetic resonance. In vitro assays on human umbilical cord vein endothelial and rat retinal cell line examined its biocompatibility and anti-oxidative capabilities, while lipopolysaccharide-stimulated murine microglia (BV2) assays measured its effects on microglial polarization. In vivo, using a mouse retinal ischemia/reperfusion (I/R) model by acute intraocular pressure elevation, the effects of CRCD on visual function, RGC apoptosis, oxidative stress, and M2 microglial polarization were examined. Results: CRCD exhibited good water solubility and anti-oxidative capabilities, in the form of free radical scavenging. In vitro, CRCD was bio-compatible and lowered oxidative stress, which was also found in vivo in the retinal I/R model. Additionally, both in vitro with lipopolysaccharide-stimulated BV2 cells and in vivo with the I/R model, CRCD was able to promote M2 microglial polarization by activating autophagy, which, in turn, down-regulated pro-inflammatory cytokines, such as IL-1β and TNF-α, as well as up-regulated anti-inflammatory cytokines, such as IL-4 and TGF-β. All these anti-oxidative and anti-inflammatory effects ultimately aided in preserving RGCs, and subsequently, improved visual function. Discussion: CRCD could serve as a potential novel treatment strategy for glaucoma, via incorporating RAPA into CDs, in turn not only mitigating its toxic side effects but also enhancing its therapeutic efficacy. Keywords: retina, ischemia/reperfusion injury, rapamycin, carbon dots, microglial polarization, autophagy Graphical Glaucoma, a neurodegenerative ocular disease, is characterized by selective, progressive, and irreversible retinal cell degeneration, particularly retinal ganglion cells (RGCs) and optic nerves, due to elevated intraocular pressure (IOP). 1,2 Retinal ischemia/reperfusion injury, caused by high IOP, is an important risk factor contributing to RGC death. Despite extensive efforts towards early diagnosis and IOP reduction, via either medical or surgical interventions, continued RGC degeneration still threatens patient visual health. 3,4 Owing to the fact that the mammalian retina lacks regenerative capacities, resulting in irreversible RGC loss, it is therefore imperative to develop alternative strategies to effectively achieve neuroprotection, as well as minimizing side effects, in order to enhance and complement current ophthalmic treatments. Along with mechanical pressure-induced injuries, IOP-induc -Abstract Truncated-

Topical administration of rapamycin promotes retinal ganglion cell survival and reduces intraocular pressure in a rat glaucoma model

Rapamycin suppresses neuroinflammation and protects retinal ganglion cell loss after optic nerve crush

Rapamycin Reduces Podocyte Apoptosis and is Involved in Autophagy and Mtor/ P70S6K/4EBP1 Signaling.

Rapamycin Induces Autophagy and Reduces the Apoptosis of Podocytes under a Stimulated Condition of Immunoglobulin A Nephropathy

Subconjunctival injection of rapamycin-loaded polymeric microparticles for effective suppression of noninfectious uveitis in rats

Rapamycin Ameliorates Experimental Autoimmune Uveoretinitis by Inhibiting Th1/Th2/Th17 Cells and Upregulating CD4+CD25+ Foxp3 Regulatory T Cells

Chitosan-Rapamycin Carbon Dots Alleviate Glaucomatous Retinal Injury by Inducing Autophagy to Promote M2 Microglial Polarization

Rapamycin prevents early steps of the development of diabetic nephropathy in rats.

Rho/Rho-associated Kinase Pathway in Glaucoma (Review).

RTA408 alleviates retinal ganglion cells damage in mouse glaucoma by inhibiting excessive autophagy

Protective effects of rapamycin on the retinal vascular bed during the vaso-obliteration phase in mouse oxygen-induced retinopathy model

Rac1 Conditional Deletion Attenuates Retinal Ganglion Cell Apoptosis by Accelerating Autophagic Flux in a Mouse Model of Chronic Ocular Hypertension.

Covalent Organic Framework (COF): A Drug and Carrier to Attenuate Retinal Ganglion Cells Death in an Acute Glaucoma Mouse Model

Rapamycin Removes Damaged Mitochondria and Protects Human Trabecular Meshwork (TM-1) Cells from Chronic Oxidative Stress

Experimental studies of rapamycin eye drops on the prevention of penetrating keratoplasty rejection in a rat model

Systemically administered peptain-1 inhibits retinal ganglion cell death in animal models: implications for neuroprotection in glaucoma

Hyperglycemia-induced VEGF and ROS production in retinal cells is inhibited by the mTOR inhibitor, rapamycin

CRISPR-CasRx-mediated disruption of Aqp1/Adrb2/Rock1/Rock2 genes reduces intraocular pressure and retinal ganglion cell damage in mice

Inhibition of the Rapamycin-Insensitive Mtorc1 /4E-BP1 Axis Attenuates TGF-β1-induced Fibrotic Response in Human Tenon's Fibroblasts

Group II metabotropic glutamate receptor agonist promotes retinal ganglion cell survival by reducing neuronal excitotoxicity in a rat chronic ocular hypertension model

Topical and systemic GLP-1R agonist administration both rescue retinal ganglion cells in hypertensive glaucoma